Emily Lawton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily Lawton has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Phan Nguyen
Thoracic Medicine Royal Adelaide Hospital Adelaide South Australia Australia
2 shared publications- Arash Badiei
Adelaide Medical School, University of Adelaide, Adelaide, SA 5000, Australia
1 shared publication Chien‐Li Holmes‐Liew
Thoracic Medicine Royal Adelaide Hospital Adelaide South Australia Australia
1 shared publication- Eugene Roscioli
School of Medicine, College of Health, Adelaide University, Adelaide, South Australia, Australia
1 shared publication - Genevieve M. Gabb
Department of Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia
1 shared publication Helen Pearce
South Australian State Emergency Service, Adelaide, South Australia, Australia
1 shared publication
Latest Publications
- Open Access
- 13 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5337
Autophagy Is Suppressed in Peripheral Blood Mononuclear Cells During Chronic Obstructive Pulmonary Disease
Assessing autophagy may offer insights into the pathogenesis of chronic obstructive pulmonary disease (COPD). However, measuring the dynamic aspect of autophagy is challenging, and sample manipulation can cause signal fluctuations that deviate from physiological conditions. We applied an organotypic method to quantify autophagy in COPD, where it frequently demonstrates disease-related dysregulation. Blood from control and COPD participants was treated with or without chloroquine. Microtubule-associated protein 1 light chain 3B II (LC3B-II) abundance was quantified in peripheral blood mononuclear cells (PBMCs), and findings were validated by transmission electron microscopy. Our observations show that while basal LC3B-II abundance was similar between groups (p = 0.60), autophagic flux was significantly lower in the COPD cohort, suggesting disruption in the regulatory factors that direct autophagosome clearance (p = 0.004). This was supported by less frequent observations of autophagy-related vacuoles in the cytosol of COPD-derived PBMCs. Our findings indicate that the suppression of autophagy can be detected in the blood of individuals with COPD, which warrants further investigation into its contribution to extrapulmonary disease processes.
- 13 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5337
Open AccessAutophagy Is Suppressed in Peripheral Blood Mononuclear Cells During Chronic Obstructive Pulmonary Disease
Assessing autophagy may offer insights into the pathogenesis of chronic obstructive pulmonary disease (COPD). However, measuring the dynamic aspect of autophagy is challenging, and sample manipulation can cause signal fluctuations that deviate from physiological conditions. We applied an organotypic method to quantify autophagy in COPD, where it frequently demonstrates disease-related dysregulation. Blood from control and COPD participants was treated with or without chloroquine. Microtubule-associated protein 1 light chain 3B II (LC3B-II) abundance was quantified in peripheral blood mononuclear cells (PBMCs), and findings were validated by transmission electron microscopy. Our observations show that while basal LC3B-II abundance was similar between groups (p = 0.60), autophagic flux was significantly lower in the COPD cohort, suggesting disruption in the regulatory factors that direct autophagosome clearance (p = 0.004). This was supported by less frequent observations of autophagy-related vacuoles in the cytosol of COPD-derived PBMCs. Our findings indicate that the suppression of autophagy can be detected in the blood of individuals with COPD, which warrants further investigation into its contribution to extrapulmonary disease processes.
- Open Access
- 10 October 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (10) , e70037
A case of VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome presenting as progressive multisystem involvement with parenchymal infiltrates following infection with Epstein Barr virus
VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, and somatic) syndrome is a rare multisystem disease affecting predominantly males over 50 and manifesting as widespread progressive inflammatory sequelae and haematological dysfunction. We describe a patient who presented with systemic symptoms of fevers, night sweats and weight loss, and developed progressive inflammatory sequelae including cutaneous lesions, haematological dysfunction, lymphadenopathy, migratory inflammatory arthropathies, with new pulmonary infiltrates, following infection with Epstein Barr Virus. Laboratory investigations, bronchoscopy, bone marrow biopsy and imaging were consistent with an inflammatory aetiology. The constellation of organ system involvement, laboratory, biopsy, and imaging results were suspicious for VEXAS syndrome, and this diagnosis was confirmed by identification of a somatic mutation in the UBA1 gene following extensive exclusion of infectious and autoimmune causes. Interestingly the onset of the VEXAS syndrome coincided with serological confirmation of Epstein Barr Virus raising the importance of further exploration into the underlying aetiology of VEXAS syndrome.
- 10 October 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (10) , e70037
Open AccessA case of VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome presenting as progressive multisystem involvement with parenchymal infiltrates following infection with Epstein Barr virus
VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, and somatic) syndrome is a rare multisystem disease affecting predominantly males over 50 and manifesting as widespread progressive inflammatory sequelae and haematological dysfunction. We describe a patient who presented with systemic symptoms of fevers, night sweats and weight loss, and developed progressive inflammatory sequelae including cutaneous lesions, haematological dysfunction, lymphadenopathy, migratory inflammatory arthropathies, with new pulmonary infiltrates, following infection with Epstein Barr Virus. Laboratory investigations, bronchoscopy, bone marrow biopsy and imaging were consistent with an inflammatory aetiology. The constellation of organ system involvement, laboratory, biopsy, and imaging results were suspicious for VEXAS syndrome, and this diagnosis was confirmed by identification of a somatic mutation in the UBA1 gene following extensive exclusion of infectious and autoimmune causes. Interestingly the onset of the VEXAS syndrome coincided with serological confirmation of Epstein Barr Virus raising the importance of further exploration into the underlying aetiology of VEXAS syndrome.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2321
New Respiratory Rapid Access Service reduces ED presentations and hospital admissions.
Aim: Increased demand for inpatient and Emergency Department (ED) healthcare, hospital congestion, and increased urgent referrals requires adaptive healthcare practises. We designed and implemented a Respiratory Rapid Access Service (RRAS) offering respiratory patients a safe, alternative urgent pathway. Methods: RRAS was implemented as a part-time pilot service. Approved pathways included direct patient contact, specialty or ED referral and expedited urgent referral review, including symptomatic malignancy. Respiratory physician review occurred within 24-72hrs in a specialist clinic. Data captured included patient demographics, medical activity, ED presentations avoided, hospital admissions prevented and qualitative patient evaluation. Results: In 10-months 393 patients were reviewed: 681 separate episodes of care. Commonest respiratory pathology was malignancy, pleural, and airways disease. RRAS prevented 359 ED presentations, saving 2129 ED hours. 181 hospital admissions avoided, and 115 early discharges facilitated, equating to 957 bed days saved. 300 urgent referrals, 115 interventional procedures and 77 MDM discussions expedited.100% patients who used RRAS deemed it an appropriate alternative to ED and 100% felt comfortable using RRAS again. Conclusion: The RRAS pilot successfully demonstrated prevention of ambulance calls, ED presentations, and hospital admissions with reduced inpatient separations and average length of stay. Expedited reviews optimised delivery of urgent care, and reduced cancer time to diagnosis via streamlined diagnostics. We will expand to full-time, offering increased urgent respiratory medical and nursing reviews, ultimately streamlining future healthcare delivery.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2321
New Respiratory Rapid Access Service reduces ED presentations and hospital admissions.
Aim: Increased demand for inpatient and Emergency Department (ED) healthcare, hospital congestion, and increased urgent referrals requires adaptive healthcare practises. We designed and implemented a Respiratory Rapid Access Service (RRAS) offering respiratory patients a safe, alternative urgent pathway. Methods: RRAS was implemented as a part-time pilot service. Approved pathways included direct patient contact, specialty or ED referral and expedited urgent referral review, including symptomatic malignancy. Respiratory physician review occurred within 24-72hrs in a specialist clinic. Data captured included patient demographics, medical activity, ED presentations avoided, hospital admissions prevented and qualitative patient evaluation. Results: In 10-months 393 patients were reviewed: 681 separate episodes of care. Commonest respiratory pathology was malignancy, pleural, and airways disease. RRAS prevented 359 ED presentations, saving 2129 ED hours. 181 hospital admissions avoided, and 115 early discharges facilitated, equating to 957 bed days saved. 300 urgent referrals, 115 interventional procedures and 77 MDM discussions expedited.100% patients who used RRAS deemed it an appropriate alternative to ED and 100% felt comfortable using RRAS again. Conclusion: The RRAS pilot successfully demonstrated prevention of ambulance calls, ED presentations, and hospital admissions with reduced inpatient separations and average length of stay. Expedited reviews optimised delivery of urgent care, and reduced cancer time to diagnosis via streamlined diagnostics. We will expand to full-time, offering increased urgent respiratory medical and nursing reviews, ultimately streamlining future healthcare delivery.
- Open Access
- 6 January 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (2) , e0898
A rare case of common variable immunodeficiency and hepatopulmonary syndrome
Hepatopulmonary syndrome (HPS) is the triad of liver disease, hypoxia and intrapulmonary shunt. In this case report, we describe an immunocompromised female with a background of common variable immunodeficiency (CVID) who presented with haemoptysis and dyspnoea. Investigations demonstrated significant hypoxaemia and intrapulmonary right‐to‐left shunting. Further evidence revealed advanced liver cirrhosis, and a diagnosis of HPS was made. This extremely rare association of CVID and HPS is one of the few cases reported in the literature.
- 6 January 2022
- Published by Wiley in Respirology Case Reports
- Vol. 10 (2) , e0898
Open AccessA rare case of common variable immunodeficiency and hepatopulmonary syndrome
Hepatopulmonary syndrome (HPS) is the triad of liver disease, hypoxia and intrapulmonary shunt. In this case report, we describe an immunocompromised female with a background of common variable immunodeficiency (CVID) who presented with haemoptysis and dyspnoea. Investigations demonstrated significant hypoxaemia and intrapulmonary right‐to‐left shunting. Further evidence revealed advanced liver cirrhosis, and a diagnosis of HPS was made. This extremely rare association of CVID and HPS is one of the few cases reported in the literature.
- 31 May 2018
- Published by Wiley in Emergency Medicine Australasia
- Vol. 31 (2) , 163-173
Review article: Environmental heatstroke and long‐term clinical neurological outcomes: A literature review of case reports and case series 2000–2016
Global temperatures are rising; extreme environmental heat can result in adverse health effects including heatstroke. Acute effects of heat are well recognised, but there is less understanding of potential long‐term adverse outcomes. Our aim was to review recent medical literature for clinical cases of environmental heatstroke with a focus on neurological outcome. Structured search strategies were designed to retrieve publications of heatstroke case reports using Ovid Medline and Embase (2000–2016). One thousand and forty‐nine abstracts were identified, and after application of exclusion criteria 71 articles deemed relevant. Ninety cases were identified from 71 articles. 100% presented with acute neurological symptoms; 87.8% presented with non‐neurological symptoms. 44.4% patients recovered fully, 23.3% died, 23.3% suffered convalescent or long‐term neurological sequelae, and in 8.9% no long‐term follow up was available. 57.1% of the patients who died or had a neurological deficit had no documented co‐morbidity. Patterns of neurological deficits included 66.7% patients with motor dysfunction, 9.5% cognitive impairment, 19% both motor and cognitive impairment and 4.7% other. In total 71.4% of the impaired patients had long‐term cerebellar dysfunction. Adverse long‐term neurological outcomes were common in surviving patients presenting with environmental heatstroke. Permanent neurological deficits were present in 34.4% of survivors where outcome was known; many were young, healthy individuals. Cerebellar injury was common suggesting cerebellar structures are vulnerable to heat. These findings highlight that people of all ages and pre‐morbid states are at risk of severe heat‐related illness. In the face of climate change, effective interventions for heat‐related illness, including both treatment and prevention are necessary.
- 31 May 2018
- Published by Wiley in Emergency Medicine Australasia
- Vol. 31 (2) , 163-173
Review article: Environmental heatstroke and long‐term clinical neurological outcomes: A literature review of case reports and case series 2000–2016
Global temperatures are rising; extreme environmental heat can result in adverse health effects including heatstroke. Acute effects of heat are well recognised, but there is less understanding of potential long‐term adverse outcomes. Our aim was to review recent medical literature for clinical cases of environmental heatstroke with a focus on neurological outcome. Structured search strategies were designed to retrieve publications of heatstroke case reports using Ovid Medline and Embase (2000–2016). One thousand and forty‐nine abstracts were identified, and after application of exclusion criteria 71 articles deemed relevant. Ninety cases were identified from 71 articles. 100% presented with acute neurological symptoms; 87.8% presented with non‐neurological symptoms. 44.4% patients recovered fully, 23.3% died, 23.3% suffered convalescent or long‐term neurological sequelae, and in 8.9% no long‐term follow up was available. 57.1% of the patients who died or had a neurological deficit had no documented co‐morbidity. Patterns of neurological deficits included 66.7% patients with motor dysfunction, 9.5% cognitive impairment, 19% both motor and cognitive impairment and 4.7% other. In total 71.4% of the impaired patients had long‐term cerebellar dysfunction. Adverse long‐term neurological outcomes were common in surviving patients presenting with environmental heatstroke. Permanent neurological deficits were present in 34.4% of survivors where outcome was known; many were young, healthy individuals. Cerebellar injury was common suggesting cerebellar structures are vulnerable to heat. These findings highlight that people of all ages and pre‐morbid states are at risk of severe heat‐related illness. In the face of climate change, effective interventions for heat‐related illness, including both treatment and prevention are necessary.